ArticleNature medicine2019
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
Erratum issuedAbstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 120 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review.BMC medicine · 2022Pooled it
- Effects of Vessel Interruption Sequence During Lobectomy for Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation.Oncogene · 2026Article
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASHuman cell · 2026Article
- Deep learning-based computed tomography quantification integrated with circulating tumor cells for prognostic evaluation in stage I lung adenocarcinoma.Quantitative imaging in medicine and surgery · 2026Article
- New proteomic signature in circulating extracellular vesicles from tumor-draining and peripheral veins of patients with lung adenocarcinoma.Cancer cell international · 2026Article
- TLyp-1-modified exosome-mediated delivery of circRAPGEF5 ASO inhibits lung adenocarcinoma metastasis via regulating the miR-570-3p/SPP1 axis.Materials today. Bio · 2025Article
- Liquid biopsy in lung cancer screening: rationale, progress, opportunities and challenges.Clinical and experimental medicine · 2025Review
- Prediction of Lung Cancer Metastasis Risk Based on Single-Cell Metabolic Profiling of Circulating Tumor Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.Cancer cell · 2025Review
- M6A-Methylated circRAPGEF5 drives lung adenocarcinoma progression and metastasis via IGF2BP2/NUP160-mediated autophagy suppression.Molecular cancer · 2025Article
- Phylogenetic inference reveals clonal heterogeneity in circulating tumor cell clusters.Nature genetics · 2025Article
- The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.Urology research & practice · 2025Article
- Establishing cM0 (i+) stage criteria in localized renal cell carcinoma based on postoperative circulating tumor cells monitoring.BMC cancer · 2025Article
- Role of circulating tumor cells in breast cancer.Breast cancer (Tokyo, Japan) · 2025Review
- Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.Cancer biology & medicine · 2024Review
- Liquid biopsy: paving a new avenue for cancer research.Cell adhesion & migration · 2024Review
- Current biological implications and clinical relevance of metastatic circulating tumor cells.Clinical and experimental medicine · 2024Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
35 authors.
Francesca Chemi *Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Dominic G Rothwell *Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Nicholas McGranahan *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sakshi GulatiClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Chris AbboshUniversity College London Cancer Institute, London, UK.
Simon P PearceClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.ORCID http://orcid.org/0000-0002-1680-5538
Cong ZhouClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Gareth A WilsonUniversity College London Cancer Institute, London, UK.
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nicolai BirkbakUniversity College London Cancer Institute, London, UK.
Jackie PierceClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Chang Sik KimClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Saba FerdousClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Deborah J BurtClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Daniel Slane-TanClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Fabio GomesCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
David MooreUniversity College London Cancer Institute, London, UK.
Rajesh ShahDepartment of Thoracic Surgery, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Crispin HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Selvaraju VeeriahUniversity College London Cancer Institute, London, UK.
Yvonne SummersDivision of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Philip CrosbieCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
Sophia WardCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Barbara MesquitaClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Marek DynowskiScientific Computing Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Dhruva BiswasCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-9141-5188
Jonathan TugwoodClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Fiona BlackhallCancer Research UK Lung Cancer Centre of Excellence, The University of Manchester, Manchester, UK.
Crispin MillerRNA Biology, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK.
Allan HackshawUniversity College London Cancer Institute, London, UK.
Ged BradyClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK. ged.brady@cruk.manchester.ac.uk.ORCID http://orcid.org/0000-0002-5009-8814
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. charles.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
Caroline DiveClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, UK. caroline.dive@cruk.manchester.ac.uk.ORCID http://orcid.org/0000-0002-1726-8850
TRACERx Consortium
Funding
Cancer Research UK 12100Cancer Research UK 15675Cancer Research UK 17786Cancer Research UK 19278Cancer Research UK 19310Cancer Research UK 20265Cancer Research UK 20465Cancer Research UK 20466Cancer Research UK 21999Cancer Research UK 22246Cancer Research UK 24956Cancer Research UK 25253Cancer Research UK 28990Cancer Research UK 29420Cancer Research UK 29569Cancer Research UK 30025Cancer Research UK A27412Medical Research Council MC_UP_1203/1Wellcome Trust 211179/Z/18/ZWellcome Trust FC001169Wellcome Trust FC001202
Abstract
Approximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery with curative intent will relapse within 5 years
Indexed as
AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleGene Expression Regulation, NeoplasticGenome, HumanHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingNeoplastic Cells, CirculatingPulmonary VeinsBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.